<DOC>
	<DOCNO>NCT02965599</DOCNO>
	<brief_summary>GSK3117391 potential complement exist therapy treatment chronic inflammatory disorder rheumatoid arthritis ( RA ) . This study evaluate efficacy , safety tolerability oral GSK3117391 ( Dose A ) administer subject severe RA despite treatment disease-modifying anti-rheumatic drug ( DMARDs ) . This randomised , double-blind ( sponsor open ) , multicentre , placebo-controlled , parallel group study . The total maximum study duration approximately 10 week . Following screening period 28 day , subject randomize ( 1:1 ) placebo GSK3117391 ( Dose A ) administer orally period 28 day . Subjects follow 7 14 day post final dose . Approximately 40 subject severe RA randomise study .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability , Pharmacokinetics Pharmacodynamics GSK3117391 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Age &gt; =18 year time signing informed consent . The subject must diagnosis RA accord 2010 ACR/ European League Against Rheumatism ( EULAR ) classification criterion RA . Functional class I , II III define 1992 ACR Classification Functional Status RA The subject must EULAR DAS 28CRP great 5.1 screening . Disease duration &gt; 6 month ( time onset patientreported symptom either pain stiffness swell hand , foot wrist ) . Swollen joint count &gt; =6 ( 66joint count ) tender joint count &gt; =8 ( 68joint count ) screen day 1 The subject must CRP serum level &gt; =5 mg/L screen The subject inadequate response intolerance DMARDs ( due lack efficacy toxicity , least 8 week treatment ) . Body weight &gt; =45 kilogram ( kg ) body mass index ( BMI ) within 18.5 35 kg/square metre ( m^2 ) inclusive . Male female requirement . Males : Male subject female partner child bear potential must comply contraception requirement time first dose study medication 91 day last dose study medication . In addition , male subject must donate sperm 91 day last dose study medication . Females : A female subject eligible participate pregnant ( confirm negative human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : Nonreproductive potential define premenopausal female one following : document tubal ligation ; document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; hysterectomy ; document Bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea . Females reproductive potential must proper establish use Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 28 day prior first dose study medication 15 week last dose study medication completion followup visit . In addition , subject require utilise barrier method contraception . A negative HCG pregnancy test , ( serum screen visit urine subsequent visit ) sensitivity least 25 international unit per litre [ IU/L ] ) require screen visit , Day 7 4 Day 1 prior dose administration . Further pregnancy test require weekly study visit followup visit . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Pregnant lactating woman . Subjects meet diagnostic criterion rheumatic disease ( example [ eg ] , lupus erythematosus , gout , psoriatic arthritis ) . Subjects previously treat 1 biologic agent ( TNF inhibitor eg . adalimumab , etanercept , infliximab , certolizumab , golimumab nonTNF inhibitor eg . abatacept , rituximab , tociluzimab ) investigational biologic . Subjects past history granulomatous disease eg . leprosy , sarcoidosis . Subjects current symptom severe , progressive , uncontrolled renal , hepatic , haematological ( include clot disorder ) , gastrointestinal ( include gastrooesophageal ulcer ) , pulmonary , cardiac ( include ischemic heart disease ) , neurological , cerebral disease , medical condition , opinion Investigator , might place subject unacceptable risk participation study . Subjects value monocyte low limit normal ( LLN ) screening . Haemoglobin &lt; 11 gram ( g ) /decilitre ( dL ) ; haematocrit &lt; 30 % , white blood cell count &lt; =3,000/cubic millimeter ( mm^3 ) ( &lt; =3.0 x 10^9/litre [ L ] ) &gt; =14,000/mm^3 ( &gt; =14 x 10^9/L ) ; platelet count &lt; = 100,000/microlitre ( μL ) ( &lt; =100x10^9/L ) ; absolute neutrophil count &lt; =2x10^9/L ; lymphocyte count &lt; 1x10^9/L screening . Alanine transaminase ( ALT ) bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) screening . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT interval ( QTc ) Fridericia 's correction formula ( QTcF ) QTc Bazett 's correction formula ( QTcB ) &gt; 450 millisecond ( msec ) ( base average triplicate electrocardiograms [ ECGs ] ) screening . Abnormal finding ECG consider clinically significant investigator . A history carcinoma situ malignant disease , except adequately treat noninvasive cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Hereditary acquire immunodeficiency disorder , include immunoglobulin deficiency . Abnormal chest Xray within 12 week Day 1 ( locally read report radiologist ) judge investigator clinicallysignificant . History infect joint prosthesis time , prosthesis still situ . History leg ulcer , catheter , chronic sinusitis recurrent chest urinary tract infection . Active infection , history recurrent infection ( exclude recurrent fungal infection nail bed ) , require management acute chronic infection follow : Currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) . Hospitalisation treatment infection within 12 week Day 1 . Use parenteral ( intravenous [ IV ] intramuscular [ IM ] ) antimicrobial ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 12 week Day 1 oral antimicrobial within 14 day Day 1 . Any surgical procedure , include bone joint surgery/synovectomy within 12 week prior Day 1 plan surgery within duration study followup period . A vaccination ( live attenuate ) within 30 day Day 1 Bacillus CalmetteGuérin ( BCG ) vaccination within 365 day Day 1 , live vaccination plan course study . The subject receive treatment therapy prohibit change treatment prescribe timeframe . Subjects previously take &gt; 1 biologic therapy RA exclude study . Other medication ( include vitamin , herbal dietary supplement ) consider casebycase basis , allow opinion investigator medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 millilitre [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Smokers would able refrain smoke whilst clinic . Subjects refrain consume follow fruit juice ( alone combination ) : seville orange , grapefruit , pummelo , citrus fruit 7 day prior first dose study medication discharge unit last dose study medication . History sensitivity component study medication , history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . Serologic evidence current/previous Hepatitis B virus ( HBV ) infection base result test Hepatitis B surface antigen ( HBsAg ) antiHepatitis B core ( antiHBc ) antibody follow within 6 week Day 1 : Subjects positive HBsAg and/or positive antiHBc antibody ( regardless antiHBs antibody status ) exclude Hepatitis C : Positive test Hepatitis C virus ( HCV ) antibody confirm subsequent blood sample Ribonucleic acid ( RNA ) polymerase chain reaction ( PCR ) assay within 6 week Day 1 . Subjects positive Hepatitis C antibody negative Hepatitis C RNAPCR assay perform subsequent sample eligible participate . Subjects positive Hepatitis C antibody positive result Hepatitis C RNAPCR assay perform subsequent sample , eligible participate . A positive test HIV 1 2 screening . Evidence active latent infection Mycobacterium tuberculosis ( TB ) , define follow : No history active latent TB infection irrespective treatment status A negative diagnostic TB test within 28 day baseline ( Day 1 ) define : A negative QuantiFERON Gold test Tspot test ( two successive indeterminate QuantiFERON test consider positive result ) OR If QuantiFERON gold Tspot test approve registered country participation , negative tuberculin skin test ( TST ) reaction per local guideline require ( strongly recommend subject history BCG vaccination test QuantiFERON gold test ) . Chest Xray within 12 week Day 1 evidence current previous pulmonary tuberculosis , locally read radiologist . Glucose6phosphate dehydrogenase ( G6PD ) deficiency . Participation trial investigational drug within 3 month 5 halflives ( whichever longer ) start study within 4 month study drug new chemical entity . Exposure 3 new chemical entity clinical study set within 12 month prior first dose day . Donation blood excess 500 mL within 56 day period prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>tolerability</keyword>
	<keyword>GSK3117391</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>